key: cord-1048990-u1niqeet
authors: Lipworth, Brian; Chan, Rory; RuiWen Kuo, Chris
title: Predicting severe outcomes in COVID-19
date: 2020-06-29
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2020.06.039
sha: d85bfef298af80b3054bc5b0e7b6cdf7b5549984
doc_id: 1048990
cord_uid: u1niqeet

nan

SARS-CoV2 infection enters via the nose, and, following aspiration to the lower respiratory tract, may then rapidly involve the lungs, resulting in severe hypoxic pneumonia. In the later stage of COVID-19 there is also a cytokine-mediated hyper-inflammatory response and coagulopathy, which in many respects simulates a viral induced multi-organ autoimmune response 1 (Figure) . Patients who tend to fare worse with more severe outcomes are males, elderly, smokers, Black and Asian people, those with obesity, along with the presence of comorbidities such as diabetes, hypertension, chronic heart, lung and kidney disease, dementia, neoplasia, and immunosuppression 2 .

Along with these various risk factors, much interest has centred around trying to identify biomarkers to predict which patients admitted to hospital with severe COVID-19 are most likely to rapidly deteriorate and require intensive care with invasive ventilation. A ratio for arterial oxygen tension (PaO2) or oxygen saturation (SaO2) to the fraction of inspired oxygen (FiO2), referred to as the P/F or S/F ratio respectively, of less than 300 is used to define the presence of respiratory failure, while a ratio of less than 100 is indicative of severe acute respiratory distress syndrome (ARDS). Some cases of ARDS with COVID-19 may be accompanied by the development of secondary hemophagocytic lymphohistiocytosis ( Figure) .

Biomarkers of hyperinflammation in COVID-19 include C reactive protein (CRP), interleukin- Taken together, these findings may have some important potential implications in the management of patients with severe COVID-19. Firstly, raised IL6 or CRP on initial presentation or rising levels during the course of the illness in conjunction with falling S/F or P/F ratio clearly indicates a need to escalate treatment. One such therapeutic intervention might be the use of systemic corticosteroids, which non-selectively suppress proinflammatory cytokines. The preliminary results from the United Kingdom RECOVERY trial in severe COVID-19 showed that, compared to 4321 patients receiving usual care, treatment with dexamethasone 6mg for 10 days in 2014 patients was associated with a 35% relative reduction in deaths after 28 days in ventilated patients and a 20% relative reduction in patients requiring oxygenation alone 8 . For patients being ventilated or oxygenated, this translated into treating 8 or 25 cases respectively with dexamethasone in order to prevent one death. It will be pertinent to know if reductions in mortality with dexamethasone were more pronounced in patients who had raised levels of CRP or IL6 or a reduced P/F ratio, either alone or combination.

We propose that a tailored biomarker approach towards endotype-guided pharmacotherapy might in turn result in improved outcomes in patients with severe COVID-19. For example, one strategy in such patients might be to escalate therapy in terms of selectively inhibiting pro-inflammatory cytokines. In this regard, we await to see the full results from randomised controlled trials with anti-IL6 agents, as preliminary data with sarilumab versus placebo reported marked reductions in CRP, which appeared to be disconnected from improvements in clinical outcomes in severe COVID-19 9 . Another approach involved selectively inhibiting IL1β with the IL1 antagonist anakinra, which in a small cohort study reduced the need for invasive ventilation and death in patients with severe COVID-19 10 . Perhaps, as is the case with dexamethasone, one might expect to see the biggest improvements with selective cytokine blockers in those patients with more critical disease where hyperinflammation and coagulopathy are most prominent.

Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Prognostic value of interleukin-6, Creactive protein, and procalcitonin in patients with COVID-19

Clinical value of immuneinflammatory parameters to assess the severity of coronavirus disease 2019

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

Prompt predicting of early clinical deterioration of moderate-to-severe COVID-19 patients: usefulness of a combined score using IL-6 in a preliminary study

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report

Anakinra for severe forms of COVID-19: a cohort study. The Lancet Rheumatology. Figure Legend SARS-CoV-2 infection enters the respiratory tract via the nose, which, in susceptible individuals, is followed by development of COVID-19 pneumonia with hypoxaemia and need for oxygenation. This may be accompanied by a profound cytokine cascade involving IL6 stimulating hepatic synthesis of CRP. Cytokine activation in turn results in ARDS and coagulopathy with release of D-dimers and